Introduction Maternal obesity is associated with a range of pregnancy complications, including fetal growth restriction (FGR), whereby a fetus fails to reach its genetically determined growth. Placental insufficiency and reduced nutrient transport play a role in the onset of FGR. Objectives Metabolomic profiling was used to reveal altered maternal and fetal metabolic pathways in a model of diet induced obesity during pregnancy, leading to reduced fetal growth. Methods We examined the metabolome of maternal and fetal livers, and placenta following a high fat and salt intake. Sprague-Dawley rats were assigned to (a) control diet (CD; 1 % salt, 10 % kcal from fat), (b) high salt diet (SD; 4 % salt, 10 % kcal from fat), (c) high fat diet (HF; 1 % salt, 45 % kcal from fat) or (d) high-fat high-salt diet (HFSD; 4 % salt, 45 % kcal from fat) 21 days prior to pregnancy and during gestation. Metabolites from maternal and fetal livers, and placenta were identified using gas and liquid chromatography combined with mass spectrometry. Results Maternal HF intake resulted in reduced fetal weight. Altered metabolite profiles were observed in the HF maternal and fetal liver, and placenta. Polyunsaturated fatty acid metabolism was significantly altered in maternal and fetal liver by maternal fat intake. Conclusion Excess of linoleic and a-linoleic acid (essential fatty acids) may be detrimental during placentation and associated with a reduction in fetal weight. Additionally, maternal, placental and fetal response to increased fat consumption seems likely to involve palmitoleic acid utilization as an adaptive response during maternal obesity.
Introduction
Increased rates of obesity and related metabolic disorders are largely attributed to high fat and sugar intake and lack of exercise. Obesogenic lifestyle choices prior to and during pregnancy have been associated with a range of maternal complications such as gestational diabetes, preterm birth and fetal growth restriction (FGR). FGR is defined as the inability of a fetus to reach its genetically determined growth potential (Kusinski et al. 2012) . Characteristics of FGR include reduced birth weight, abnormal placentation, fetal hypoglycaemia, hypoxia and increased fetal cortisol concentrations (Economides et al. 1991; Kovo Karen Mumme and Clint Gray have contributed equally.
Electronic supplementary material The online version of this article (doi:10.1007/s11306-016-1014-9) contains supplementary material, which is available to authorized users. Kyriakakou et al. 2009; Mayhew et al. 2003) . FGR is associated with 43-50 % of stillbirths (Gardosi et al. 2005; McCowan et al. 2007 McCowan et al. , 2013 and 42 % of early neonatal deaths (Roex et al. 2012) in the Western World. The metabolic changes associated with maternal obesity such as insulin resistance, hypertension, elevated triglycerides, increased systemic inflammatory profiles and oxidative stress can lead to placental insufficiency (Hajer et al. 2008; Huang et al. 2014 ) and mitochondrial abnormalities in the placenta (Mele et al. 2014) . Similarly, excessive fat and/or salt intake during pregnancy may not provide the optimal balance of nutrients conducive to fetal growth and placental nutrient transfer, thereby resulting in a state of fetal malnutrition (Ay et al. 2009 ).
To date, the use of metabolomics in pregnancy studies has largely been utilised to identify unique metabolic profiles prior to the onset of disease with an aim to develop effective biomarkers and screening tests (Austdal et al. 2015a, b; Diaz et al. 2013; Kenny et al. 2010) . In a comprehensive study of human plasma metabolic profiles in pregnancies complicated by reduced fetal weight, a phenotypic signature of reduced fetal growth was identified; this was validated in an animal model of placental insufficiency (Horgan et al. 2011) . Beside the biomarker discovery, metabolomics studies are also focused on the mechanisms controlling proper development of the pregnancy, targeting placental, maternal and fetal metabolome shifts during gestation (Fanos et al. 2013; Hill et al. 2011) . Sensitive placental phenotyping related to preeclamptic pregnancies with fetal growth restriction has identified several altered metabolic pathways (Austdal et al. 2015a, b) . However, the influence of maternal fat and salt intake alone or in combination on maternal-fetal and placental metabolic profiles has not been examined previously. The current study, using state of the art metabolomics techniques, provides evidence that obesogenic maternal diet negatively impacts on the developing fetus and placental transfer which may potentiate risk of maternal metabolic disruption and subsequent reductions in fetal weight. Our study offers a robust nutritional paradigm in which the mechanistic aspects of maternal metabolism, placental transfer and subsequent fetal growth disruptions may be better understood.
Materials and methods

Animal experiments
Eighty female Sprague-Dawley rats were fed a standard control chow diet ad libitum from weaning until day 90 of age and maintained at 25°C and a 12 h light: 12 h dark cycle. Rats were then randomly assigned to one of four dietary groups and fed ad libitum for 21 days prior to pregnancy and throughout gestation. The experimental groups were fed either (1) Control (CD) purified standard chow diet (1 % NaCl, 10 % kcal from fat); (2) 4 % Salt diet (SD; 4 % NaCl, 10 % kcal from fat); (3) High-fat diet (HF; 1 % NaCl, 45 % kcal from fat) or (4) High-fat 4 % Salt (HFSD; 4 % NaCl, 45 % kcal from fat) (Research Diets, New Jersey; USA, Supplementary Materials, Table S1 ). Female rats (115 days of age ± 2) were timemated using an estrous cycle monitor (Fine Science Tools, USA). Day 1 of pregnancy was determined by the presence of spermatozoa after a vaginal lavage and females individually housed thereafter. Food and water intake and body weight of dams were recorded every 2 days. Subgroup of the pregnant dams (n = 8/dietary group) were weighed, anaesthetised using isofluorane and killed by decapitation at the day 18 of gestation. Fetuses were excised from the mother, separated from the placenta and sexed by anogenital distance; fetal body weight and placental weight were recorded. All fetuses were then killed by decapitation. Maternal and fetal livers were excised and weighed. Tissues were snap frozen in liquid nitrogen and stored at -80°C until further analysis. All animal procedures were approved by the Animal Ethics Committee of the University of Auckland (approval R1069).
Statistical analysis of maternal and fetal physiological data
Statistical analysis was performed using SigmaPlot for Windows version 12.0 (Systat Software Inc., San Jose, CA). All the other data were analyzed by two-way factorial ANOVA, with maternal high fat and maternal high salt as factors. Holm-Sidak post hoc tests were performed to detect further differences between groups. Differences between groups were considered significant at p \ 0.05. All data are presented as mean ± SEM unless otherwise stated.
Chemicals and reagents
L-Alanine-2,3,3,3-d 4 , Indole-d 5 , sodium hydroxide, pyridine and methyl chloroformate (MCF) were purchased from Sigma Aldrich (St. Louis, MO, USA). Methanol and chloroform were obtained from Merck (Darmstadt, Germany). Sodium bicarbonate and anhydrous sodium sulphate were purchased from Ajax Finechem (NSW, Australia).
Metabolite extraction
In total 27 maternal liver samples, 28 female placentas and 27 male placentas, 28 female livers and 27 male livers underwent metabolomics analysis (n = 7/6 per dietary group). 100 mg of each frozen tissue was ground using an autolyser (TissueLyser II, Qiagen). Sample and methanol/ water solutions were kept on dry ice prior to extraction. Each sample was extracted three times with different methanol/water mixture. Firstly, 1000 lL of 50 % methanol/water solution was added along with internal standards -40 lL of 10 mM d 4 alanine and 40 lL of 0.5 mM d 5 tryptophan, and vortexed. Samples were centrifuged at -5°C, 3500 rpm for 5 min. Following supernatant collection, the same procedure was performed using 80 and 100 % methanol. Combined methanol extracts were vortexed and divided into two aliquots: 1000 lL for liquid chromatography-mass spectrometry (LC-MS) and 1500 lL for gas chromatography-mass spectrometry (GC-MS) analysis. 100 lL from each sample was taken and pooled. This was then divided into QC samples respective to each tissue group and diet. Samples were dried by SpeedVac (Thermo Scientific Savant SC250EXP SpeedVac Concentrator with a Savant RVT4104 Refrigerated Vapor Trap) for 5 h (no heat, 0.8 torr vacuum pressure) and subsequently stored at -80°C for chromatography analysis.
GC-MS and LC-MS analysis
GC-MS dedicated metabolic extracts were processed using a methyl chloroformate (MCF) method and analyzed in accordance with the protocol published by Smart et al. (Smart et al. 2010) . Samples dedicated for LC-MS analysis were kept on ice and processed in the same random order as GC-MS samples. The dried samples were re-suspended in 300 lL of chilled MQ water and centrifuged for 15 min at 12,000 rpm at 4°C. 200 lL was transferred into a LC-MS vial and loaded for analysis. The samples were analysed by UHPLC-MS; Accela 1250 coupled to a Q-Exactive Orbitrap mass spectrometry system (Thermo Fisher Scientific Inc., MA, USA) operating in heated electrospray ionisation mode. Samples were analysed consecutively in positive ion mode. Chromatographic separations were performed using a Syncronis C18 column (100 9 2.1 mm, 1.7 lm; Thermo Fisher Scientific, Auckland, New Zealand). Solvent A and B were 0.1 % formic acid in water and 0.1 % formic acid in acetonitrile, respectively. A flow rate of 0.40 mL/min was applied with a gradient elution profile (95 % A for 30 s and subsequently ramped to 99 % B at 13 min, followed by a 2 min hold at 99 % B before a rapid return to 95 % A over 1 min and re-equilibrated for 4 min). The column and samples were maintained at temperatures of 30 and 4°C, respectively. A 5 lL tissue sample volume was injected. Centroid MS scans were acquired in the mass range of 80 -1200 m/z using the Orbitrap mass spectrometer with mass resolution of 35,000 (FWHM as defined at m/z 400), AGC 1 e6, IT 100 ms, Sheath gas 40, Aux gas 10, Sweep gas 5, Spray voltage 4.00 kV, Capillary temperature 320°C, S-lens RF 50.0, and heater temperature 0°C.
Data analysis
GC-MS data
Raw data from the GC-MS platform were directly processed with ChemStation Agilent software (MSD ChemStation E.01.00.237, 1989-2008 Agilent Technologies Inc., CA, USA) and converted to a NetCDF format. Data was deconvoluted and an ion report was produced using AMDIS v2.71 (NIST, Boulder, CO, USA) (Stein 1999) . Metabolites were identified using in-house MS library and Metab 3, an upgrade of an in-house R-script Metab (Aggio et al. 2011) , compatible with R v3.0.2 (R Development Core Team 2008).
LC-MS data
Raw data from LC-MS was processed using SIEVE (version 2.1.377, Thermo Fisher). Frame settings were to include molecules where; mass to charge ratio was between 85 and 1200, and a retention time between 0 and 15 min with bypassed alignment. Unaligned data were framed with parameters of 1000 m/z width ppm, ICIS peak integration, retention time width of 1 min and abundance greater than 5 9 10 7 . As some of the resulting frames, based on a width of 1 min, contained more than one peak, the raw data was processed a second time with a reduced width of 12 s. SIEVE data processing resulted in a data matrix of retention time, ion mass and a given frame intensity.
Metabolite identification
All GC-MS metabolites were identified using in-house MCF derivatives library according to the electron impact fragmentation mass spectrum and retention time (Supplementary Materials, Table S2 ). In line with Zhang et al. (2014) unidentified fatty acids with fragment patterns of mass to charge ratio (m/z) 55, indicating one double bond in the structure, were classified as a monounsaturated fatty acid (MUFA). Unknowns with fragments m/z 67 and 79 suggesting two or more double bonds were classified as polyunsaturated fatty acids (PUFA).
LC-MS data was analysed using PutMedID software (Brown et al. 2011) and metabolites with an H? adduct were used for identification. Only statistically significant frames from LC-MS were assessed for validity i.e. one peak in each frame and correct integration. PutMedID, publicly available software (http://www.mcisb.org), was used to help with putative identification. PutMedID default settings for positive mode were used.
GC-MS and LC-MS metabolite identification given in the figures was based on four proposed levels of reporting standards for chemical analysis according to Sumner et al. (Sumner et al. 2007 ).
Metabolic pathway analysis
Significant differences in metabolites identified following univariate analysis led to pathway analysis in MetPA (MetabolAnalyst 2.0) (Xia and Wishart 2011) to identify potential pathways likely to be involved in the occurrence of reduced fetal weight. Differences between groups were considered significant at p \ 0.05.
Statistical analysis of the metabolomics data
GC-MS and LC-MS data were normalised by the abundance of the internal standard (d 4 -alanine for GC-MS and d 5 -tryptophan for LC-MS) and the weight of the sample (*100 mg). Normalised data were log-transformed and statistical analysis was performed using R software. A mixed-effects three-way ANOVA was performed, with fat, salt and fetal sex as main factors (Gueorguieva and Krystal 2004) . A student t test was performed to calculate metabolite differences between purified experimental diets. To minimise the risk of increasing Type 1 errors through multiple comparisons, the false discovery rate (FDR) was controlled using a Benjamini Hochberg (BH) adjustment (Benjamini and Hochberg 1995) . Differences between groups were considered significant at p \ 0.05 after the FDR adjustment. PCA analyses were performed using Pareto scaled values. Linear regression was performed on selected metabolites for significant correlations.
Results
Effect of diet on maternal weight
A significant effect of fat (p = 0.04) was observed; dams in both HF and HFSD groups were heavier than CD and SD group dams. An overall effect of fat (p = 0.049) was observed in HF-fed dam liver weights after adjusting for body weight (Table 1) .
Effect of maternal diet on fetal and placental weights
An overall effect of fat (p = 0.044) was observed on male fetal body and liver weight (p = 0.049); both HF and HFSD groups had reduced body weight and liver weight (Table 2 ). An interaction effect (p = 0.002) was observed in male placentas due to maternal HF reducing placental weight and fetal body weights in HFSD, being partially restored with the inclusion of salt in the maternal diet (HFSD). Following post hoc analysis, weight of HF male placentas were significantly less than all other groups (p \ 0.05) and HFSD placental weights significantly lower than CD and SD only (p \ 0.05) ( Table 2) . In females, an interaction effect (p = 0.010) was observed on body weight, with maternal HF fetuses had a reduced body weights when compared to all other groups. However, with the introduction of salt into the diet (HFSD), this was reversed. Following post hoc analysis, female HF fetuses had a significantly lower body weight when compared to all other groups (Table 2 ).
An overall effect of salt (p = 0.02) was observed in combined male and female fetal weight as both SD and HFSD fetuses were heavier than CD and HF fetuses. An overall effect of fat (p \ 0.001) and an interaction effect (p \ 0.001) remained when male and female placental data was merged. Pooled fetal liver weight had an overall effect of fat (p \ 0.03).
Effect of maternal diet on placental metabolism
Following isotopes and adducts removal from the LC-MS data, a total of 262 placental GC-MS and LC-MS metabolic features underwent statistical analysis. Six metabolic peaks from GC-MS analysis were identified as significantly different in placental tissue in response to a HF maternal diet compared to control diet after the FDR adjustment (p \ 0.001; Fig. 1 ). Significantly identified metabolic peaks belonged to the lipid class. Five out of six peaks were increased in the placenta with levels of palmitoleic acid reduced in response to a maternal HF diet. Principal Component Analysis (PCA) also revealed differences between HF and CD placenta (Fig. 2) . The principal metabolites influencing this separation were again from the lipids class. A pathway analysis identified the biosynthesis of unsaturated fatty acids (p \ 0.001), linoleic acid metabolism (p = 0.01) and alpha linolenic acid metabolism (p = 0.03) as being significantly altered in maternal HF placentas.
None of the metabolic peaks from GC-or LC-MS were classified as significantly different in response to a maternal SD with respect to salt following FDR adjustment.
Effects of maternal diet on the maternal and fetal hepatic metabolome
A total of 220 liver metabolic features underwent statistical analysis from GC-and LC-MS data. Thirteen metabolic peaks from GC-and LC-MS were identified to significantly differ in response to a maternal HF diet (Fig. 3) . Metabolic profiles did not change in response to a maternal SD and no interactions were observed. Common significant alterations in response to maternal HF diet for both maternal and fetal liver were observed only for 2 metabolites. Palmitoleic acid was significantly reduced by the maternal HF diet in both the maternal (p \ 0.0001, after FDR adjustment) and fetal livers (p = 0.01, after FDR adjustment). The other metabolite down regulated by the high-fat maternal diet belonged to the polyunsaturated fatty acids group (PUFA), but could not be further identified. Fetal liver linoleic acid and its derivatives increased in response to the maternal HF diet, but no differences were observed in the maternal liver. Pathway analysis identified the biosynthesis of unsaturated fatty acids (p \ 0.001) and linoleic acid metabolism (p = 0.02) as a significantly altered pathway in the fetal liver.
3.5 Fetal sex differences in placenta and fetal liver unrelated to maternal diet Statistical analysis revealed that fetal sex had no effect on the differences observed in relation to HF and/or salt intake.
Metabolic composition of the control and highfat purified diets used in the study
Following FDR adjustment, 30 metabolic peaks from 149 were identified as significantly different between CD and HF purified diets. 11 metabolites, primarily lipids, were Dams were fed one of four diets: control (CD, n = 8); high salt (SD, n = 8); high fat (HF, n = 8) and high fat and salt (HFSD, n = 8). Holm-Sidak post hoc tests were performed to detect any differences between groups, with * indicating significantly different from CD (p \ 0.05). Data presented as mean ± SEM NS non-significant Maternal diet: control (CD, n = 71 (male, n = 37, female, n = 34)); high salt (SD, n = 92 (male, n = 45, female n = 47)); high fat (HFD, n = 85 (male, n = 45, female n = 40)) and high fat and salt (HFSD, n = 94, (male n = 37, female n = 57). Data were analysed by ANOVA with fat and salt as factors. Holm-Sidak post hoc tests were performed to detect any differences between groups, with * indicating significantly different from CD, and # indicating significantly different from HFSD (p \ 0.05) NS non-significant increased and 19 metabolites, primarily amino acids, were decreased in the HF diet compared to the CD diet (Fig. 4) .
Discussion
Results presented here emphasize the importance of a nutritionally balanced diet during pregnancy and those considering pregnancy. Changes in maternal metabolites, particularly lipid moieties, following exposure to HF consumption can have detrimental consequences on fetal growth and development. There is extensive evidence that maternal obesity is associated with obstetric complications (Anderson et al. 2013; McDonald et al. 2010; Salihu et al. 2009 ). Reduced fetal weight and increased numbers of stillbirths are observed in experimental models of maternal obesity (Hayes et al. 2012; Howie et al. 2009 ). Changes in rodent placental blood vessel maturation, reduced growth in the labyrinth, reduced placental weights related to HF diet have also been reported (Akyol et al. 2009; Hayes et al. 2012; Mark et al. 2011) . However, metabolomic analysis has rarely been utilised to investigate biochemical pathways that may lead to disrupted placentation and fetal growth. We therefore utilised a well-established model of maternal diet-induced obesity to examine potential mechanisms involved in the metabolic disturbances leading to reduced fetal weight. In the current study, alterations in metabolic profiles following a maternal HF diet were observed in the placenta and fetal liver. This was evident by significant increases in essential fatty acids (EFA) and long-chain PUFA (LCPUFA). EFAs can include linoleic acid (C18:2n-6) and a-linolenic acid (C18:3n-3), which are both converted to the LCPUFA such as docosahexaenoic acid (C22:6n-3) and eicosapentaenoic acid (C20:5n-3by desaturation (D5-and D6-desaturases) and elongation enzymes. EFAs are an important external dietary source as humans and rats cannot synthesise EFAs endogenously (Innis 2008) . Therefore, the fetus relies solely on the maternal supply of EFAs. As LCPUFAs are essential to brain and retina development previous studies have shown that an excess of these lipids may have a negative effect on fetal and placental development (Uauy et al. 2001) . Our study shows that placenta and fetal liver from HF-fed mothers had higher concentrations of linoleic, a-linolenic and 11,14-eicosadeienoic acids. Interestingly, the HF purified diet contained higher levels of n-6, thereby increasing the n-6:n-3 PUFA ratio. It has been suggested that an increase in this ratio is Maternal control diet is constant at 1. Identification (ID) of metabolites: 1 = identified compounds, 2 = putatively annotated compounds, 3 = putatively characterised compound classes, 4 = unknown compound. Platform: GC gas chromatography mass-spectrometry; LC liquid chromatography mass-spectrometry. Significances are indicated by *p \ 0.05, **p \ 0.01, ***p \ 0.001 Fig. 2 Score plot of significant metabolic peaks in the placenta in response to a maternal HF diet. Principal Component Analysis were performed using Pareto scaled values detrimental to the placenta via promotion of inflammatory processes (Simopoulos 2011) . Cetin et al. (2002) also reported changes in EFAs and LCPUFA in fetal plasma in FGR compared to normal human fetuses, however, the dietary fat intake in these subjects was not determined.
The pathway involving the biosynthesis of unsaturated fatty acids was affected by maternal HF intake in the placenta and the fetal liver. Pathways converting the saturated palmitic (C16:0) and stearic acid (C18:0) into monounsaturated palmitoleic (C16:1) and oleic acid (C18:1) by the rate-limiting enzymes stearoyl-CoA desaturase in the placenta and fetal liver were primarily altered by a maternal HF diet. Palmitoleic acid is an omega-7 MUFA, which is commonly found in the liver and is a prominent constituent of adipose tissue and primarily sourced from food or desaturated from palmitic acid (C16:0). In the current study, decreased palmitoleic acid (C16:1n-7c) was observed in all three tissues, in response to the maternal HF diet. This was unexpected as both palmitic and palmitoleic acids were significant components of the HF purified diet. However, palmitoleic acid increases insulin sensitivity, suppresses pro-inflammatory gene expression and improves hepatic lipid metabolism in mice (Yang et al. 2011) . Fatty acids with different degrees of saturation have different effects on insulin sensitivity and lipid metabolism. Diets rich in palmitoleic acid improve circulating lipid profiles in animals (Matthan et al. 2009 ) and humans (Garg et al. 2007 ). Palmitoleic acid functions as an adipose tissuederived lipid hormone, stimulating muscle insulin action and suppressing hepatosteatosis (Cao et al. 2008) . Given the effects on palmitoleic acid, we speculate that palmitoleic acid was metabolised by the maternal, placental and fetal tissues to counteract the seemingly negative effects of saturated fatty acids on maternal metabolism, which could, in part, explain the decrease in concentrations compared to the control diet. However, further research is necessary to investigate the exact pathways involved in the palmitoleic acid utilization and its direct effects on placentation and the fetal growth. As palmitic acid concentrations were not different in any tissues, we speculate that the surplus C16:0 in HF diets was stored in adipose tissue or utilised as energy as suggested by PPARa and GLUT2 expression in the same cohort of animals (Reynolds et al. 2014) .
Analysis of purified HF and CD diets showed that the abundance of most dietary amino acids was significantly lower in the maternal HF diet. However, this did not correspond to altered metabolism in the placenta or maternal and fetal liver. Previous studies of FGR suggest that in a
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-Heptadecenoic acid (C17:1n-8t) AND/OR 10-Heptadecenoic acid (C17:1n-7t)*** 2 GC
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Linoleic acid (C18:2n-6,9c)*** 2 GC <O> 11,14-Eicosadienoic (C20:2n-6,9c)*** 3 GC <-O-> bishomo-gamma-linolenic acid (C20:3n-6,9,12c) AND/OR 11,14,17-Eicosatrienoic acid (C20:3n-3,6,9c) AND/OR Arachidonic acid (C20:4n-6,9,12,15c)* hypoxic placenta, amino acid transport capacity is reduced (Regnault et al. 2013) . Down regulation of the fetal oxidative metabolism and growth rate results in normal or even higher concentrations of amino acids in the FGR fetuses compared to the healthy controls. In the current study, this may explain why no observable differences in the hepatic or placental amino acids abundance were seen between the dietary groups. In the same cohort of animals, previously published data from our group showed that amino acid transporters were also altered (Reynolds et al. 2014) .
Concluding remarks
In conclusion, EFAs, are necessary for fetal development. However, we showed that excessive EFAs may disrupt placentation and subsequent fetal growth, contributing to FGR. We speculate that maternal, placental and fetal response to saturated fatty acid excess involves palmitoleic acid utilization as a potential adaptive mechanism during maternal obesity, which may play an important role in the development or predisposition to FGR. Control diet is constant at 1. Identification (ID) of metabolites: 1 = identified compounds, 2 = putatively annotated compounds, 3 = putatively characterised compound classes, 4 = unknown compound. Platform: GC gas chromatography mass-spectrometry; LC liquid chromatography mass-spectrometry. Logged data were analysed by t-test. Significances are indicated by *p \ 0.05, **p \ 0.01, ***p \ 0.001
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